FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2905880887> ?p ?o ?g. }

• W2905880887 endingPage "363" @default.
• W2905880887 startingPage "354" @default.
• W2905880887 abstract "Background Chronic anticoagulation is recommended in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative to warfarin, but there are limited data to support their use in patients with HCM and AF. We sought to compare thromboembolic events, bleeding, and mortality between NOAC and warfarin in patients with HCM and AF. Methods From the Korean National Health Insurance Service database during the period from January 1, 2011, to December 31, 2016, we identified a warfarin-treated group of patients with HCM and AF (n = 955) who were compared with a 1:2 propensity-matched NOAC treated group (n = 1,504). Results After a median follow-up of 16 months, the incidence rates of ischemic stroke and major bleeding were similar between NOAC- and warfarin-treated patients with HCM and AF. NOAC-treated patients had lower incidence rates for all-cause mortality (5.11 and 10.13 events per 100 person-years for NOAC and warfarin groups) and the composite of fatal cardiovascular events (0.77 and 1.80 events per 100 person-years). Compared with warfarin, use of NOACs was associated with a significantly lower risk of all cause-mortality (hazard ratio, 0.43; 95% CI, 0.32-0.57) and composite fatal cardiovascular events (hazard ratio, 0.39; 95% CI, 0.18-0.82). Conclusions Compared with warfarin, patients with HCM and AF on NOACs had similar stroke and major bleeding risks, but lower all-cause mortality and composite fatal cardiovascular events. Our data suggest that patients with HCM and AF can be safely and effectively treated with NOACs. Chronic anticoagulation is recommended in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative to warfarin, but there are limited data to support their use in patients with HCM and AF. We sought to compare thromboembolic events, bleeding, and mortality between NOAC and warfarin in patients with HCM and AF. From the Korean National Health Insurance Service database during the period from January 1, 2011, to December 31, 2016, we identified a warfarin-treated group of patients with HCM and AF (n = 955) who were compared with a 1:2 propensity-matched NOAC treated group (n = 1,504). After a median follow-up of 16 months, the incidence rates of ischemic stroke and major bleeding were similar between NOAC- and warfarin-treated patients with HCM and AF. NOAC-treated patients had lower incidence rates for all-cause mortality (5.11 and 10.13 events per 100 person-years for NOAC and warfarin groups) and the composite of fatal cardiovascular events (0.77 and 1.80 events per 100 person-years). Compared with warfarin, use of NOACs was associated with a significantly lower risk of all cause-mortality (hazard ratio, 0.43; 95% CI, 0.32-0.57) and composite fatal cardiovascular events (hazard ratio, 0.39; 95% CI, 0.18-0.82). Compared with warfarin, patients with HCM and AF on NOACs had similar stroke and major bleeding risks, but lower all-cause mortality and composite fatal cardiovascular events. Our data suggest that patients with HCM and AF can be safely and effectively treated with NOACs." @default.
• W2905880887 created "2019-01-01" @default.
• W2905880887 creator A5005370459 @default.
• W2905880887 creator A5015102556 @default.
• W2905880887 creator A5027765634 @default.
• W2905880887 creator A5041455638 @default.
• W2905880887 creator A5050000016 @default.
• W2905880887 creator A5056336513 @default.
• W2905880887 creator A5057554500 @default.
• W2905880887 creator A5072211804 @default.
• W2905880887 creator A5073037699 @default.
• W2905880887 creator A5088579117 @default.
• W2905880887 creator A5089459141 @default.
• W2905880887 date "2019-02-01" @default.
• W2905880887 modified "2023-09-30" @default.
• W2905880887 title "Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy" @default.
• W2905880887 cites W1789003475 @default.
• W2905880887 cites W1982902653 @default.
• W2905880887 cites W2061475341 @default.
• W2905880887 cites W2085975373 @default.
• W2905880887 cites W2097618980 @default.
• W2905880887 cites W2124691949 @default.
• W2905880887 cites W2132213773 @default.
• W2905880887 cites W2152623033 @default.
• W2905880887 cites W2160180604 @default.
• W2905880887 cites W2162586165 @default.
• W2905880887 cites W2340266043 @default.
• W2905880887 cites W2442037294 @default.
• W2905880887 cites W2463106066 @default.
• W2905880887 cites W2509795914 @default.
• W2905880887 cites W2521940263 @default.
• W2905880887 cites W2605653750 @default.
• W2905880887 cites W2607953695 @default.
• W2905880887 cites W2623061081 @default.
• W2905880887 cites W2738896442 @default.
• W2905880887 cites W2742791693 @default.
• W2905880887 cites W2750856436 @default.
• W2905880887 cites W2757839063 @default.
• W2905880887 cites W2760485286 @default.
• W2905880887 cites W2761376614 @default.
• W2905880887 doi "https://doi.org/10.1016/j.chest.2018.11.009" @default.
• W2905880887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30472021" @default.
• W2905880887 hasPublicationYear "2019" @default.
• W2905880887 type Work @default.
• W2905880887 sameAs 2905880887 @default.
• W2905880887 citedByCount "51" @default.
• W2905880887 countsByYear W29058808872019 @default.
• W2905880887 countsByYear W29058808872020 @default.
• W2905880887 countsByYear W29058808872021 @default.
• W2905880887 countsByYear W29058808872022 @default.
• W2905880887 countsByYear W29058808872023 @default.
• W2905880887 crossrefType "journal-article" @default.
• W2905880887 hasAuthorship W2905880887A5005370459 @default.
• W2905880887 hasAuthorship W2905880887A5015102556 @default.
• W2905880887 hasAuthorship W2905880887A5027765634 @default.
• W2905880887 hasAuthorship W2905880887A5041455638 @default.
• W2905880887 hasAuthorship W2905880887A5050000016 @default.
• W2905880887 hasAuthorship W2905880887A5056336513 @default.
• W2905880887 hasAuthorship W2905880887A5057554500 @default.
• W2905880887 hasAuthorship W2905880887A5072211804 @default.
• W2905880887 hasAuthorship W2905880887A5073037699 @default.
• W2905880887 hasAuthorship W2905880887A5088579117 @default.
• W2905880887 hasAuthorship W2905880887A5089459141 @default.
• W2905880887 hasBestOaLocation W29058808872 @default.
• W2905880887 hasConcept C120665830 @default.
• W2905880887 hasConcept C121332964 @default.
• W2905880887 hasConcept C126322002 @default.
• W2905880887 hasConcept C127413603 @default.
• W2905880887 hasConcept C164705383 @default.
• W2905880887 hasConcept C207103383 @default.
• W2905880887 hasConcept C2776301958 @default.
• W2905880887 hasConcept C2776704044 @default.
• W2905880887 hasConcept C2779161974 @default.
• W2905880887 hasConcept C2780185194 @default.
• W2905880887 hasConcept C2780645631 @default.
• W2905880887 hasConcept C44249647 @default.
• W2905880887 hasConcept C50382708 @default.
• W2905880887 hasConcept C61511704 @default.
• W2905880887 hasConcept C71924100 @default.
• W2905880887 hasConcept C78519656 @default.
• W2905880887 hasConceptScore W2905880887C120665830 @default.
• W2905880887 hasConceptScore W2905880887C121332964 @default.
• W2905880887 hasConceptScore W2905880887C126322002 @default.
• W2905880887 hasConceptScore W2905880887C127413603 @default.
• W2905880887 hasConceptScore W2905880887C164705383 @default.
• W2905880887 hasConceptScore W2905880887C207103383 @default.
• W2905880887 hasConceptScore W2905880887C2776301958 @default.
• W2905880887 hasConceptScore W2905880887C2776704044 @default.
• W2905880887 hasConceptScore W2905880887C2779161974 @default.
• W2905880887 hasConceptScore W2905880887C2780185194 @default.
• W2905880887 hasConceptScore W2905880887C2780645631 @default.
• W2905880887 hasConceptScore W2905880887C44249647 @default.
• W2905880887 hasConceptScore W2905880887C50382708 @default.
• W2905880887 hasConceptScore W2905880887C61511704 @default.
• W2905880887 hasConceptScore W2905880887C71924100 @default.
• W2905880887 hasConceptScore W2905880887C78519656 @default.
• W2905880887 hasIssue "2" @default.
• W2905880887 hasLocation W29058808871 @default.

• next